Raia Drogasil S.A. (RADLY) Stock: Price, Forecast & Analyst Target
Raia Drogasil S.A. (RADLY) — price $2.36 (-3.28%), as of the Nov 19, 2026 trading session; market cap $4.13B. Expected results Mar 2, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Raia Drogasil S.A. · RADLY · Healthcare · Medical - Pharmaceuticals
Raia Drogasil SA engages in the retail sale of medicine, perfumery, personal care and beauty products, cosmetics and dermocosmetics.
Price as of Nov 19, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $2.36 | |
| Change on the day | -3.28% | |
| 52-week range | $2.36–$5.34 | |
| Market capitalisation | $4.13B | — |
| Price / earnings (trailing) | 19.21 | |
| Shares traded on the day | 1.6K | |
| Beta (volatility vs the S&P 500) | 0.01 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · below the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings results · in line with the recorded estimate
- · Earnings results · in line with the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
How to read these dates
Estimated dates can change.
Other perspectives
Council score for Raia Drogasil (RADLY): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 9, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Raia Drogasil (RADLY), and what does it report?
Short answer
Raia Drogasil SA engages in the retail sale of medicine, perfumery, personal care and beauty products, cosmetics and dermocosmetics. Healthcare / Medical Pharmaceuticals Headquarters: Av. Corifeu de Azevedo Marques, 3097, São Paulo, SP, 05339-900, BR. It employs 73,895 people and is led by Renato Raduan. In Q3 FY2026 it reported revenue of R$11.41B and net income of R$408M. The market values it at $4.13B.
What do the latest results show for Raia Drogasil (RADLY)?
Short answer · as of
The most recent reported quarter, Q3 FY2026, carried revenue of R$11.41B. Against analyst estimates the company has EPS beat 3 of the last 8 reports.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $2.08B Nov 3, 2026
- Latest report · revenue estimate
- $2.43B Nov 3, 2026
- Latest report · revenue vs estimate
- Below estimate Nov 3, 2026
- Latest report · EPS vs estimate
- In line Nov 3, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Nov 3, 2026 | $2.08B | $2.43B | $0.0500 | $0.0500 |
| Aug 4, 2026 | $2.16B | $2.32B | $0.0500 | $0.0500 |
| May 6, 2026 | $2.43B | $2.36B | $0.0249 | $0.0334 |
| Mar 3, 2026 | $2.33B | $2.29B | $0.0334 | $0.0398 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2026 | R$11.41B | R$408M | R$0.24 (diluted) |
| Q2 FY2026 | R$11.31B | R$434M | R$0.25 (diluted) |
| Q1 FY2026 | R$10.57B | R$159M | R$0.09 (diluted) |
| Q4 FY2025 | R$12.29B | R$310M | R$0.18 (diluted) |
What are the financial strengths and risks for Raia Drogasil (RADLY)?
Short answer · as of
The distress and quality screens read Altman Z 3.29 · Piotroski F 7. Trailing ratios: ROE 17.6% · ROA 5.0% · current ratio 1.40 · earnings yield 5.3% · free-cash-flow yield 5.1%.
What should you watch next at Raia Drogasil (RADLY)?
Short answer · as of
The next earnings report is expected on Mar 2, 2027. Current published price targets run low $5.20 · high $5.20 · consensus $5.20 · median $5.20 against a quoted price of $2.36 (as of Nov 19, 2026).
What the records here don't tell us
- Detailed statement figures are not shown because their conversion to USD has not been verified.
- No forward revenue or earnings estimate is on file.
- No insider Form 4 transaction falls inside the window this page reads.
- Fewer than two score snapshots exist, so no score trend is shown.
Checked against the records this page reads, on the dates shown above.
How is Raia Drogasil scored?
Research dated 2026-09-13.
The core distinction between Raia Drogasil and generic merchandise retailers is its defensive product mix, heavily weighted toward essential medications and health supplies that resist broad economic pullbacks.
Unlike pure online retail platforms, the business relies on an extensive physical logistics footprint across multiple states, tying its valuation directly to the efficiency of its regional distribution centers rather than simple digital customer acquisition. This combined reliance on essential healthcare demand and discretionary beauty segments allows the company to balance steady prescription traffic with higher-margin cosmetic purchases.
| Company | Price | Market value | Score |
|---|---|---|---|
| $14.88 Nov 19, 2026 | $5.85B | — Model unavailable | |
| $27.20 Nov 19, 2026 | $7.41B | — Model unavailable | |
| $6.87 Nov 19, 2026 | $5.09B | — Model unavailable | |
| $14.09 Nov 19, 2026 | $6.72B | — Model unavailable | |
| $92.00 Nov 19, 2026 | $4.53B | — Model unavailable | |
| $24.30 Nov 19, 2026 | $1.50B | — 5-pillar · not comparable | |
| $9.07 Nov 19, 2026 | $589M | — 5-pillar · not comparable | |
| $403.60 Nov 18, 2026 | $46.1B | — 5-pillar · not comparable | |
| $2.29 Nov 19, 2026 | $204M | — 5-pillar · not comparable | |
| $18.75 Nov 19, 2026 | $133M | — 5-pillar · not comparable | |
| $5.80 Nov 19, 2026 | $123M | — 5-pillar · not comparable | |
| $1.61 Nov 19, 2026 | $57.9M | — 5-pillar · not comparable |
The comparison model is unavailable. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $5.20 – $5.20
- Consensus target
- $5.20
- Median target
- $5.20
Consensus record · Captured .
Measured against a quoted price of $2.36 (as of Nov 19, 2026).
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held RADLY in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported RADLY in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Raia Drogasil (RADLY)?
Common Questions About RADLY (Healthcare)
These answers are editorial: 1 of these 8 answers is drawn from the RADLY research dossier (written Jun 15, 2026 by gpt-4o-mini); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is RADLY a good stock to buy?
Stock Expert AI does not rate RADLY buy, sell or hold. Raia Drogasil S.A. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the RADLY stock price today?
The last price recorded for Raia Drogasil S.A. (RADLY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the RADLY price target?
The analyst consensus price target for Raia Drogasil S.A. (RADLY), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What are the main risks for RADLY?
Raia Drogasil faces several risks, including potential regulatory changes that could affect the pharmaceutical retail landscape. Additionally, the company contends with intense competition from other pharmacy chains, which could pressure margins.
What are the key factors to evaluate for RADLY?
Evaluate RADLY on fundamentals, analyst consensus, and risk factors. To weigh it, compare the trailing P/E under Price & valuation with the analyst view under Analyst targets & estimates on this page. Not financial advice.
How frequently does RADLY data refresh on this page?
RADLY's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven RADLY's recent stock price performance?
Raia Drogasil S.A. (RADLY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider RADLY overvalued or undervalued right now?
The trailing P/E of Raia Drogasil S.A. (RADLY) is listed under Price & valuation, and the analyst consensus target under Analyst targets & estimates, on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 43 figures on this page — 36 from Financial Modeling Prep (FMP), 4 with no recorded source, 2 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com